PPARA and chronic myelogenous leukemia, BCR-ABL1 positive: In a study by Wang et al. (2012), PPAR-α agonists significantly enhanced the anti-leukemic effects of imatinib in KCL22 cells and CD34+ primary cells through up-regulating the SLC22A11 gene expression and increasing the uptake of imatinib by CML cells [218].